Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard B Warren

Showing results (91-100 of 257) with videos related to

Pageof 26
Sort By:
Rheumatology and Therapy|March 6, 2024
Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect ComparisonPhilip J Mease, Richard B Warren, Peter Nash, et al.
Dermatology and Therapy|November 4, 2023
Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative ReviewAndrew Blauvelt, Richard G Langley, Kenneth B Gordon, et al.
Rheumatology (Oxford, England)|July 21, 2022
Association between psoriatic disease and lifestyle factors and comorbidities: cross-sectional analysis and Mendelian randomizationSizheng Steven Zhao, Eftychia Bellou, Suzanne M M Verstappen, et al.
Dermatology and Therapy|November 8, 2025
Comparison of All-Cause Mortality in Generalized Pustular Psoriasis and Plaque Psoriasis: A Systematic Review and Meta-AnalysisBruce Strober, Lluís Puig, Mark G Lebwohl, et al.
The Journal of Dermatological Treatment|February 16, 2022
Remote consultations: an audit of the management of dermatology patients on biologics during the first wave of the COVID-19 pandemicChiedu E Ufodiama, Sarah J J Touyz, David A Fitzgerald, et al.
The British Journal of Dermatology|May 25, 2023
Effectiveness and survival of methotrexate versus adalimumab in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)Oras A Alabas, Kayleigh J Mason, Zenas Z N Yiu, et al.
Dermatology and Therapy|December 5, 2025
Deucravacitinib in Plaque Psoriasis After Inadequate Response to Apremilast: Phase 3 POETYK AnalysisApril W Armstrong, Richard B Warren, Howard Sofen, et al.
The British Journal of Dermatology|April 30, 2023
Imsidolimab, an anti-interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phase II GALLOP trialRichard B Warren, Adam Reich, Andrzej Kaszuba, et al.
Rheumatology and Therapy|August 9, 2024
Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect ComparisonPhilip J Mease, Richard B Warren, Peter Nash, et al.
Journal of the American Academy of Dermatology|December 30, 2019
Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysisRichard B Warren, Melinda Gooderham, Russel Burge, et al.
Pageof 26

Showing results (91-100 of 257) with videos related to

Sort By:
Pageof 26
Rheumatology and Therapy|March 6, 2024
Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect ComparisonPhilip J Mease, Richard B Warren, Peter Nash, et al.
Dermatology and Therapy|November 4, 2023
Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative ReviewAndrew Blauvelt, Richard G Langley, Kenneth B Gordon, et al.
Rheumatology (Oxford, England)|July 21, 2022
Association between psoriatic disease and lifestyle factors and comorbidities: cross-sectional analysis and Mendelian randomizationSizheng Steven Zhao, Eftychia Bellou, Suzanne M M Verstappen, et al.
Dermatology and Therapy|November 8, 2025
Comparison of All-Cause Mortality in Generalized Pustular Psoriasis and Plaque Psoriasis: A Systematic Review and Meta-AnalysisBruce Strober, Lluís Puig, Mark G Lebwohl, et al.
The Journal of Dermatological Treatment|February 16, 2022
Remote consultations: an audit of the management of dermatology patients on biologics during the first wave of the COVID-19 pandemicChiedu E Ufodiama, Sarah J J Touyz, David A Fitzgerald, et al.
The British Journal of Dermatology|May 25, 2023
Effectiveness and survival of methotrexate versus adalimumab in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)Oras A Alabas, Kayleigh J Mason, Zenas Z N Yiu, et al.
Dermatology and Therapy|December 5, 2025
Deucravacitinib in Plaque Psoriasis After Inadequate Response to Apremilast: Phase 3 POETYK AnalysisApril W Armstrong, Richard B Warren, Howard Sofen, et al.
The British Journal of Dermatology|April 30, 2023
Imsidolimab, an anti-interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phase II GALLOP trialRichard B Warren, Adam Reich, Andrzej Kaszuba, et al.
Rheumatology and Therapy|August 9, 2024
Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect ComparisonPhilip J Mease, Richard B Warren, Peter Nash, et al.
Journal of the American Academy of Dermatology|December 30, 2019
Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysisRichard B Warren, Melinda Gooderham, Russel Burge, et al.
Pageof 26